Tesamorelin

Egrifta · GHRH Analog

FDA-approved GHRH analog for visceral fat reduction

Typical Dose

1–2 mg per day

Route

Subcutaneous

Frequency

Once daily, in the morning

Cycle

3–6 months

Overview

Tesamorelin is a synthetic version of a hormone your brain naturally produces to tell your pituitary gland to release growth hormone. It is FDA-approved for a specific condition that causes excess belly fat in HIV patients, but it is also used off-label by people who want to reduce deep abdominal fat (called visceral fat) and improve their body composition. Visceral fat is the dangerous kind that wraps around your organs — not just the kind you can pinch.

Key Benefits

Reduces visceral (abdominal) fat significantly

Improves body composition

Increases IGF-1 levels

Improves cognitive function (studied)

Cardiovascular benefits

Mechanism of Action

Tesamorelin tells your pituitary gland (a small gland at the base of your brain) to release growth hormone in natural pulses, the same way your body does it on its own. That growth hormone then signals your body to break down stored fat for energy, particularly the deep belly fat around your organs. It also raises IGF-1, a growth factor that supports muscle maintenance and overall body composition.

Dosing Protocol

Typical Dose

1–2 mg per day

Dose Range

1–2 mg/day

Frequency

Once daily, in the morning

Route

Subcutaneous injection

Cycle Length

3–6 months

CLINICAL NOTES

Best taken in the morning on an empty stomach. Results are typically seen within 3 months.

Save to Library

Reconstitution calculator and cycle planner pre-filled with Tesamorelin defaults

Side Effects & Safety

Injection site reactions

Fluid retention (edema)

Joint pain

Glucose intolerance

Carpal tunnel syndrome (rare)

IMPORTANT DISCLAIMER

This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol. Individual responses vary and medical supervision is recommended.